Initial uptake in use of sildenafil in general practice

European Journal of Clinical Pharmacology

Volumn 56, Issue 12, 2001, Pages 911-914

  Williams, David ^a   Feely, John ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

General practice; Pharmacoepidemiology; Sildenafil

Indexed keywords

NITRATE; PHOSPHODIESTERASE INHIBITOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; SILDENAFIL; SULFONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; ERECTILE DYSFUNCTION; GENERAL PRACTICE; HUMAN; IRELAND; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY;

ADOLESCENT; ADULT; AGED; DRUG INTERACTIONS; ERECTILE DYSFUNCTION; FAMILY PRACTICE; HUMANS; IRELAND; MALE; MIDDLE AGED; NITRATES; PHARMACOEPIDEMIOLOGY; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONES;

EID: 0034465547     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000255     Document Type: Article

References (21)

1. Dinsmore W, Evans C (1999) ABC of sexual health: erectile dysfzunction. BMJ 318:387-390
2. Chisholm J (1999) Viagra: a botched test case for rationing. BMJ 318:273-274
3. Beecham L (1999) News. UK issues guidance on prescribing Viagra. BMJ 318:279
4. Payne D (1999) Scripts for Viagra to be free in Ireland. BMJ 318:1578
5. Feely J (1992) The influence of pharmacoeconomic factors on prescribing patterns in Ireland. Pharmacoeconomics 2:99-106
6. General Medical Services (Payments) Board (1998) Financial and statistical analysis of claims and payments 1998. GMS
7. WHO Collaborating Centre for Drug Statistics Methodology (1999) Anatomical therapeutic chemical (ATC) classification index including defined daily doses (DDDs) for plain substances.
8. Morley J, Kaiser F (1992) Impotence in elderly men. Drugs Aging 2:330
9. Food and Drug Administration (2000) Postmarketing safety of sildenafil citrate (Viagra): summary of reports of death in Viagra users received from marketing (late March) through mid-November 1998. online:http/;'www.fda.gov/-cder/consumerinfo/viagra;safety3.htm
10. Perrin J (1998) And then came Viagra. Pharm J 260:707
11. Rosen RC (1996) Erectile dysfuction: the medicalisation of male sexuality. Clin Psychol Rev 16:497-519
12. Steers W (1999) Viagra after one year. Urology 54:12-17
13. Burns-Cox N, Gingell C (1998) Medical management of erectile dysfunction. Postgrad Med J 74:336-342
14. Hackett G (1995) Impotence. The most neglected complication of diabetes. Diabetes Res 28:75-83
15. Stolk E, Busschbach J, Caffa M, Meuleman E, Rutten F (2000) Cost utility analysis of sildenafil compared with papaverine-phentolamine injections. BMJ 320:1-5
16. Freemantle N (2000) Valuing the effects of sildenafil in erectile dysfunction: strong assumptions are required to generate a QALY value. BMJ 320:1156-1157
17. Smith K, Roberts M (2000) The cost-effectiveness of sildenafil. Ann Intern Med 132:933-937
18. Morales A, Gingell C, Collins M, Wicker P, Osterloh I (1998) Clinical safety of oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction. Int J Impot Res 16:69-74
19. Pfizer Limited S1 (1998) Sildenafil. Summary of product characteristics, UK and Ireland
20. Cheitlin M, Hutter A, Brindis R, Ganz P, Kaul S, Russell R, Zusman R (1999) Use of Sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol 33:273-282
21. Herrmann H, Chang G, Klugherz B, Mahoney P (2000) Hemodynamic effects of sildenafil in men with severe coronary artery disease. NEJM 342:1622-1626